Nakamura, K.; Asanuma, K.; Okamoto, T.; Yoshida, K.; Matsuyama, Y.; Kita, K.; Hagi, T.; Nakamura, T.; Sudo, A.
GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas. Cancers 2022, 14, 814.
https://doi.org/10.3390/cancers14030814
AMA Style
Nakamura K, Asanuma K, Okamoto T, Yoshida K, Matsuyama Y, Kita K, Hagi T, Nakamura T, Sudo A.
GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas. Cancers. 2022; 14(3):814.
https://doi.org/10.3390/cancers14030814
Chicago/Turabian Style
Nakamura, Koichi, Kunihiro Asanuma, Takayuki Okamoto, Keisuke Yoshida, Yumi Matsuyama, Kouji Kita, Tomohito Hagi, Tomoki Nakamura, and Akihiro Sudo.
2022. "GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas" Cancers 14, no. 3: 814.
https://doi.org/10.3390/cancers14030814
APA Style
Nakamura, K., Asanuma, K., Okamoto, T., Yoshida, K., Matsuyama, Y., Kita, K., Hagi, T., Nakamura, T., & Sudo, A.
(2022). GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas. Cancers, 14(3), 814.
https://doi.org/10.3390/cancers14030814